Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

Bibliografske podrobnosti
Main Authors:	Gold, R, Kappos, L, Palace, J, Siever, A, Marrosu, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Comi, G
Format:	Conference item
Izdano:	2012

Podobne knjige/članki

Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study
od: Kappos, L, et al.
Izdano: (2012)

Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS
od: Comi, G, et al.
Izdano: (2012)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
od: Gold, R, et al.
Izdano: (2014)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study
od: Gold, R, et al.
Izdano: (2014)

Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
od: Gold, R, et al.
Izdano: (2014)

Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neurology (2014) 261 (267-276) DOI: 10.1007/s00415-013-7115-8)
od: Gold, R, et al.
Izdano: (2014)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
od: Jeffrey A. Cohen, et al.
Izdano: (2019-09-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
od: Burcu Altunrende, et al.
Izdano: (2017-12-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
od: Vahid Shaygannezhad, et al.
Izdano: (2017-08-01)

Combination treatment of fingolimod with antidepressants in relapsing–remitting multiple sclerosis patients with depression: a multicentre, open-label study – REGAIN
od: Antonios Bayas, et al.
Izdano: (2016-09-01)

CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
od: Rizaldy Taslim Pinzon, et al.
Izdano: (2017-11-01)

Oral fingolimod to treat multiple sclerosis: see your cardiologist first
od: Douglas Kazutoshi Sato, et al.
Izdano: (2014-09-01)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
od: Fatemeh Yavari, et al.
Izdano: (2021-03-01)

Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis
od: Scott Joseph Sonne, et al.
Izdano: (2020-09-01)

Efficacy and Safety of Fingolimod in an Unselected Patient Population.
od: Maria Rasenack, et al.
Izdano: (2016-01-01)

A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis
od: Claudia Fracasso, et al.
Izdano: (2022-06-01)

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
od: Zi-Ye Song, et al.
Izdano: (2014-01-01)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
od: Stanley Cohan MD, PhD, et al.
Izdano: (2015-03-01)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
od: Gajofatto A, et al.
Izdano: (2015-12-01)

Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis
od: Druart C, et al.
Izdano: (2017-12-01)

Fingolimod for Irradiation-Induced Neurodegeneration
od: Judith Metzdorf, et al.
Izdano: (2019-07-01)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
od: Tony Sehr, et al.
Izdano: (2020-05-01)

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East
od: Anat Achiron, et al.
Izdano: (2017-08-01)

Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
od: Canan Duman İlki, et al.
Izdano: (2020-03-01)

Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis
od: Meng-Chuan Lu, et al.
Izdano: (2020-04-01)

A randomized, open-label study assessing the bioequivalence of two formulations of Fingolimod 0.5 mg in healthy subjects
od: Mario Tanguay, et al.
Izdano: (2018-03-01)

3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
od: Nevin John, et al.
Izdano: (2024-08-01)

Double Filtration Plasmapheresis Treatment of Refractory Multiple Sclerosis Relapsed on Fingolimod: A Case Report
od: Roberto De Masi, et al.
Izdano: (2020-10-01)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
od: Guillermo Izquierdo, et al.
Izdano: (2017-01-01)

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence
od: Bhupendra O. Khatri
Izdano: (2016-03-01)

004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis
od: Marco Onofrj, et al.
Izdano: (2021-08-01)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
od: Rozita Doosti, et al.
Izdano: (2021-04-01)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
od: Abdoreza Naser Moghadasi, et al.
Izdano: (2020-07-01)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
od: Manish Singh, et al.
Izdano: (2011-01-01)

Safety of generic fingolimod
od: O. M. Koval, et al.
Izdano: (2018-03-01)

Weight Loss and Fingolimod
od: Nefati Kıylıoğlu
Izdano: (2017-12-01)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
od: Martin Vališ, et al.
Izdano: (2023-08-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
od: Duygu Tap, et al.
Izdano: (2020-12-01)

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
od: Francisco Barrero, et al.
Izdano: (2020-01-01)

Advances in the treatment of relapsing&ndash;remitting multiple sclerosis &ndash; critical appraisal of fingolimod
od: Gasperini C, et al.
Izdano: (2013-03-01)